Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi PharmaTech to Build $100 Million R&D Center in Wuhan

publication date: Aug 11, 2010
WuXi PharmaTech will spend $100 million to build a new R&D facility in the central China city of Wuhan. The company will construct a 40,000 sq meter CRO facility in the Wuhan National Biological Industry Base (Optics Valley of BioLake). Wuhan sources told ChinaBio® that a cooperative agreement between WuXi and the Wuhan Biological Base was signed on August 9. More details....

Stock Symbol: (NYSE: WX)

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital